The Lp(a) Journey
November 14, 2024
Professor Henry Ginsberg, Co-Chair of the Lp(a) Forum, looks at progress in Lp(a) science that has led to multiple Lp(a) targeting agents in development.
The Unanswered Questions
November 14, 2024
Professor John Chapman, Co-Chair of the Lp(a) Forum, considers key questions about Lp(a) atherogenicity, including the heterogeneity of the Lp(a) proteome and lipidome.
Who’s who in the Lp(a) proteome?
November 14, 2024
Professor Sally McCormick, University of Otago, New Zealand, discusses key research that has provided important insights into the role of the Lp(a) proteome.
The proinflammatory Lp(a) lipidome
November 19, 2024
Dr Jeffrey Kroon, Amsterdam UMC, The Netherlands, dives deeper into the atherogenicity of Lp(a) with a focus on the pro-inflammatory lipidome.
Update on lipid lowering therapies: Muvalaplin
November 19, 2024
Professor Stephen Nicholls, Monash University, Clayton, Australia, reports early phase clinical data on the oral Lp(a) lowering small molecule, muvalaplin.
Update on lipid lowering therapies: Olpasiran
November 14, 2024
Dr Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents data on the siRNA, olpasiran, from the Phase 2 OCEAN(a) DOSE study.
Update on lipid lowering therapies: Pelacarsen
November 14, 2024
Professor Steve Nissen, Cleveland Clinic, Ohio, USA, discusses Phase 2 data about the effects of the liver-targeted antisense oligonucleotide, pelacarsen, on Lp(a).
Update on lipid lowering therapies: Lepodisiran
November 14, 2024
Dr Ann Marie Navar, University of Texas Southwestern Medical Center, Dallas, USA, presents data from a Phase 1 ascending dose study of the siRNA, lepodisiran.
Update on lipid lowering therapies: Zerlasiran
November 14, 2024
Professor Steve Nissen, Cleveland Clinic, Ohio, USA, reviews progress with the siRNA, zerlasiran, in early phase Lp(a) lowering clinical trials.
Lp(a) is an extremely atherogenic lipoprotein: Relevance to primary and secondary prevention
November 19, 2024
Dr Gissette Reyes-Soffer, Columbia University, New York, USA, sets the scene for discussions about Lp(a) atherogenicity and its relevance to primary and secondary prevention.
